Articles Archive - Page 200 of 816

An Important Message from the ACR on the Death of George Floyd

From the College | June 11, 2020

The American College of Rheumatology is deeply troubled by the recent events surrounding the death of George Floyd. This tragedy is the latest in a long history of senseless killings of people of color. We recognize that racial inequality is an invisible undercurrent impacting the lives of many of our members and patients, and we…

Novel Cathepsin K Inhibitor Promising for OA

Lara C. Pullen, PhD | June 10, 2020

Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…

Serological Antibody Tests in COVID-19: Test Reliability and Utility

Ruth Jessen Hickman, MD | June 10, 2020

Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

Ethics Forum: Medical Ethical Considerations for COVID-19

David Y. Chen, MD, PhD, & Eric J. Gapud, MD, PhD, on behalf of the ACR Committee for Ethics & Conflicts of Interest | June 8, 2020

Prescribing stewardship is just one ethical consideration facing rheumatologists during the COVID-19 pandemic.

FDA Approves Celecoxib in an Oral Solution

Michele B. Kaufman, PharmD, BCGP | June 8, 2020

The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…

Advocacy During a Pandemic: An Update from the Government Affairs Committee

Blair Solow, MD | June 5, 2020

Although the COVID-19 outbreak has shifted the focus and approach of advocacy efforts, ACR staff and the Government Affairs Committee continue to work on behalf of rheumatology providers and patients.

ACR Continues to Advocate Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments

From the College | June 5, 2020

Despite efforts by the ACR and other organizations, Blue Cross Blue Shield of Tennessee has indicated that it will move forward with implementation of its specialty pharmacy acquisition mandate on July 1, 2020.

Influential Lancet Article on HCQ Retracted

Michael Erman | June 5, 2020

NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…

2 Pediatric Indications Sought for Golimumab

Michele B. Kaufman, PharmD, BCGP | June 3, 2020

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis

Will Boggs, MD | June 3, 2020

NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…